 | | Vol. 12.39 – 6 October, 2020 |
| |
|
|
| Scientists used high-throughput chromosome conformation enhancer capture to interrogate the role of enhancer-to-enhancer interactions during differentiation of human MSCs.
[Nature Genetics] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | | Researchers used peptide amphiphiles (PAs) to coassemble with and organize extracellular matrix (ECM) proteins producing tunable 3D models of the tumor microenvironment. They included specific epitopes, PA nanofibers, and ECM macromolecules for the 3D culture of human ovarian cancer, endothelial, and mesenchymal stem cells.
[Science Advances] |
| | Investigators assessed whether multilineage MSCs, best known for immunomodulation toward T cells, could be therapeutic for highly virulent bacterial infections via modulation of polymorphonuclear neutrophils.
[Cell Reports] |
| | Scientists showed that CD8+ T cells played an important role in MSC-mediated acute lung injury remission, and both infiltration quantity and proinflammatory function were inhibited by MSCs, indicating a potential mechanism for therapeutic intervention.
[Cell Death & Disease] |
| | MSCs were activated with LPS following a short one hour exposure or long-time exposure for 48hrs, and then, scientists evaluated the biological response in vitro, the immunosuppressive capacity of MSCs in vitro, and the therapeutic potential of MSCs in an experimental autoimmune encephalomyelitis (EAE) mouse model.
[Stem Cell Research & Therapy] |
| | The authors investigated in vitro cellular networks derived from human gingival mesenchymal stem cells (hGMSCs) and calcium phosphate (CaP) bioceramic interaction.
[Scientific Reports] |
| | Preconditioning with ethionamide promoted the proliferation of Wharton’s jelly-derived MSCs by activating phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase (MEK)/extracellular signal-regulated kinase 1/2 signaling.
[International Journal of Molecular Sciences] |
| | Different scaffold configurations were characterized in terms of morphology and a mechanical response, and their interactions with two types of stem cells and bone marrow MSCs were assessed.
[Polymers] |
| |
|
|
| Investigators showed that H3.3K36me3 loss on mutant H3.3 altered the deposition of the repressive H3K27me3 mark from intergenic to genic regions, beyond areas of H3.3 deposition. This promoted redistribution of other chromatin marks and aberrant transcription, altering cell fate in mesenchymal progenitors and hindering differentiation.
[Cancer Discovery] |
|
|
|
| Researchers explored whether exosomes derived from circAkap7-modified adipose-derived MSCs have therapeutic effects on cerebral ischemic injury.
[Frontiers in Cell and Developmental Biology] |
|
|
|
| Investigators compared the therapeutic effects of various delivery routes when administering Good Manufacturing Practice (GMP)-grade human umbilical cord-MSCs in a rodent model of subacute-phase stroke.
[Frontiers in Cellular Neuroscience] |
|
|
|
|
| The authors examine the various factors to be considered when developing a hMSC manufacturing process using microcarriers and bioreactors and their potential impact on the final product.
[Biotechnology Advances] |
|
|
|
| Harnessing the immunomodulatory properties of MSCs to ameliorate the ‘cytokine-storm’ immune response to coronavirus disease 2019 (COVID-19), can indeed provide a golden key for the treatment of COVID-19 patients, especially severe cases.
[Frontiers in Cell and Developmental Biology] |
|
|
|
|
| OrganaBio, LLC announced the launch of the MesenPACâ„¢-MSC platform (comprised of placenta- and umbilical cord-derived mesenchymal stem/stromal cells) and ImmunoPACâ„¢ product lines, designed to support translational researchers in their quest to rapidly develop next generation cell-based therapies. These products provide a unique and timely solution to critical supply chain issues that are hindering the regenerative medicine, cell therapy, gene therapy, and immunotherapy arenas.
[OrganaBio, LLC (Businesswire, Inc.)] |
|
|
|
| Cynata Therapeutics has produced trial results confirming the initial success of its Cymerus MSCs in restoring cardiac function following a heart attack.
[The West Australian] |
|
|
|
| Avalon GloboCare Corp. provided a clinical update on its chimeric antigen receptor (CAR) T-cell therapy and allogeneic MSC therapy programs following successful completion of its Phase I clinical trial of AVA-001, the company’s leading CAR T-cell therapy candidate in development for patients with relapsed/refractory B-cell lymphoblastic leukemia.
[Avalon GloboCare Corp. (GlobeNewswire, Inc.)] |
|
|
|
|
| January 25 – January 27 , 2021
Virtual |
|
|
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Terasaki Research Institute – Los Angeles, California, United States |
|
|
|
| | National University of Ireland Galway – Galway, Ireland |
|
|
|
| | Zhejiang University – Zhejiang, China |
|
|
|
| | Pennsylvania State University – Philadelphia, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
